The earnings report is expected to be good and therefore i think there will at least be a gap fill up to 5.
Looking at the macd it also looks like we are gonna have a green crossover to the upwards movement. I wouldsay bullish.
I could be completely wrong and this should be taken with a grain of salt
SNIPER STRATEGY (new version)
It works ALMOST ON ANY CHART.
It produces Weak, Medium and Strong signals based on consisting elements.
NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear.
TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS.
ENTRY PRICE BLACK COLOR
TARGETS GREEN COLOR
STOP LOSS RED COLOR
DO NOT USE THIS...
AGEN hasn't done this in years...what? It hasn't sustained these levels for any meaningful amount of time. I did a quick fib retracement using those 2017 highs as the upper anchor and you can see what has revealed itself. The 236 area is a key pivot. Most of the time it has acted as a resistance pivot. But, so far AGEN has held these levels. Where does it go from...
The July 8th candle made a bullish engulfing candle and on the the 9th AGEN gapped up slightly to open and closed above the 1 fib level (5.57). This looks very bullish in my opinion. Also on the 4 hour chart the MACD crossed.
Looking for a close over 5.66 to avoid a double top. If so targeting $6.67 short term.
This week will be a potentially big one (in either direction for AGEN imo and it will come down to the data to tell which way the stock breaks...or breaks down.
This week, AGEN stock could be on the list of penny stocks to watch. Two posters will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting from June 4 – 8, 2021.The focus...
My Post-FDA Over-The-Weekend Watchlist:
$GLYC
$ONCT
$ONCY
$PIRS
$AGEN
All of these biotechs have phase one cancer treatment clinical-trial data releases this weekend. Based on my research, these are the ones that I think are most likely to release good data. Since they are all in phase one, it is likely that we see a gap up on Monday and a solid downtrend from...
Fundamental Analysis:
Agenus Inc. is an immuno-oncology company that develops technologies to treat cancers and other infectious diseases. One drug that they are developing, AGEN1181 , has undergone phase 1/2 safety trials. The results from these trials were released on February 9, 2021, and the results will be presented at AACR on April 10, 2021. AGEN1181 is...
My biotech watchlist for this week:
FDA Hype
$GLYC
$AGEN
$GLSI
$ONCY
$MTEM
$ALPN
$ALPN
$CMPI
$ATXI
Potential Swings
$CTXR
$UBX
$ZLAB
Like and follow for weekly bio watchlists :) Also please comment your favorite tickers; I would love to hear what you guys think.
Happy Trading!
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.
NASDAQ
